skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
Material Type:
Artigo 		Adicionar ao Meu Espaço

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Chau, I. ; Haag, G.M. ; Rahma, O.E. ; Macarulla, T.M. ; McCune, S.L. ; Yardley, D.A. ; Solomon, B.J. ; Johnson, M. ; Vidal, G.A. ; Schmid, P. ; Argiles, G. ; Dimick, K. ; Mahrus, S. ; Abdullah, H. ; He, X. ; Sayyed, P. ; Barak, H. ; Bleul, C. ; Cha, E. ; Drakaki, A.

Annals of oncology, 2018-10, Vol.29, p.viii439-viii440 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
1806P Analysis of germ-line mutations in non-syndromic malignancies with concurrent pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, and RAD51C/D
1806P Analysis of germ-line mutations in non-syndromic malignancies with concurrent pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, and RAD51C/D
Material Type:
Artigo 		Adicionar ao Meu Espaço

1806P Analysis of germ-line mutations in non-syndromic malignancies with concurrent pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, and RAD51C/D

Miller, E.M. ; Mullins, J. ; Jain, A. ; Chaudhry, A. ; Mi, D. ; Usman, R. ; Jones, T. ; Baca, Y. ; Xiu, J. ; Korn, W.M. ; Cummings, S. ; Vidal, G.

Annals of oncology, 2021-09, Vol.32, p.S1229-S1229 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
3
1239TiPMORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
1239TiPMORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
Material Type:
Artigo 		Adicionar ao Meu Espaço

1239TiPMORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Chau, I ; Haag, G M ; Rahma, O E ; Macarulla, T M ; McCune, S L ; Yardley, D A ; Solomon, B J ; Johnson, M ; Vidal, G A ; Schmid, P ; Argiles, G ; Dimick, K ; Mahrus, S ; Abdullah, H ; He, X ; Sayyed, P ; Barak, H ; Bleul, C ; Cha, E ; Drakaki, A

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
4
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Conteduca, V. ; Wetterskog, D. ; Sharabiani, M.T.A. ; Grande, E. ; Fernandez-Perez, M.P. ; Jayaram, A. ; Salvi, S. ; Castellano, D. ; Romanel, A. ; Lolli, C. ; Casadio, V. ; Gurioli, G. ; Amadori, D. ; Font, A. ; Vazquez-Estevez, S. ; González del Alba, A. ; Mellado, B. ; Fernandez-Calvo, O. ; Méndez-Vidal, M.J. ; Climent, M.A. ; Duran, I. ; Gallardo, E. ; Rodriguez, A. ; Santander, C. ; Sáez, M.I. ; Puente, J. ; Gasi Tandefelt, D. ; Wingate, A. ; Dearnaley, D. ; Demichelis, F. ; De Giorgi, U. ; Gonzalez-Billalabeitia, E. ; Attard, G.

Annals of oncology, 2017-07, Vol.28 (7), p.1508-1516 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Grasselli, J. ; Elez, E. ; Caratù, G. ; Matito, J. ; Santos, C. ; Macarulla, T. ; Vidal, J. ; Garcia, M. ; Viéitez, J.M. ; Paéz, D. ; Falcó, E. ; Lopez Lopez, C. ; Aranda, E. ; Jones, F. ; Sikri, V. ; Nuciforo, P. ; Fasani, R. ; Tabernero, J. ; Montagut, C. ; Azuara, D. ; Dienstmann, R. ; Salazar, R. ; Vivancos, A.

Annals of oncology, 2017-06, Vol.28 (6), p.1294-1301 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
Material Type:
Artigo 		Adicionar ao Meu Espaço

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

Sartor, O. ; Heinrich, D. ; Mariados, N. ; Méndez Vidal, M.J. ; Keizman, D. ; Thellenberg Karlsson, C. ; Peer, A. ; Procopio, G. ; Frank, S.J. ; Pulkkanen, K. ; Rosenbaum, E. ; Severi, S. ; Trigo Perez, J.M. ; Wagner, V. ; Li, R. ; Nordquist, L.T.

Annals of oncology, 2017-10, Vol.28 (10), p.2464-2471 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy
Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy

Vidal, A.D. ; Thalmann, G.N. ; Karamitopoulou-Diamantis, E. ; Fey, M.F. ; Studer, U.E.

Annals of oncology, 2015-02, Vol.26 (2), p.374-377 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Frenel, J.S. ; Kim, J.W. ; Aryal, N. ; Asher, R. ; Berton, D. ; Vidal, L. ; Pautier, P. ; Ledermann, J.A. ; Penson, R.T. ; Oza, A.M. ; Korach, J. ; Huzarski, T. ; Pignata, S. ; Colombo, N. ; Park-Simon, T.W. ; Tamura, K. ; Sonke, G.S. ; Freimund, A.E. ; Lee, C.K. ; Pujade-Lauraine, E.

Annals of oncology, 2022-10, Vol.33 (10), p.1021-1028 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Material Type:
Artigo 		Adicionar ao Meu Espaço

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Paré, L. ; Pascual, T. ; Seguí, E. ; Teixidó, C. ; Gonzalez-Cao, M. ; Galván, P. ; Rodríguez, A. ; González, B. ; Cuatrecasas, M. ; Pineda, E. ; Torné, A. ; Crespo, G. ; Martin-Algarra, S. ; Pérez-Ruiz, E. ; Reig, Ò ; Viladot, M. ; Font, C. ; Adamo, B. ; Vidal, M. ; Gaba, L. ; Muñoz, M. ; Victoria, I. ; Ruiz, G. ; Viñolas, N. ; Mellado, B. ; Maurel, J. ; Garcia-Corbacho, J. ; Molina-Vila, M Á ; Juan, M. ; Llovet, J.M. ; Reguart, N. ; Arance, A. ; Prat, A.

Annals of oncology, 2018-10, Vol.29 (10), p.2121-2128 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling
Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling

Gonçalves-Ribeiro, S. ; Sanz-Pamplona, R. ; Vidal, A. ; Sanjuan, X. ; Guillen Díaz-Maroto, N. ; Soriano, A. ; Guardiola, J. ; Albert, N. ; Martínez-Villacampa, M. ; López, I. ; Santos, C. ; Serra-Musach, J. ; Salazar, R. ; Capellà, G. ; Villanueva, A. ; Molleví, D.G.

Annals of oncology, 2017-09, Vol.28 (9), p.2160-2168 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.